// App-Quantinova.ai

775TiP : KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Researchers

Presenter

  • R.S.Finn

Principal Investigators

  • S.L.Chan

  • A.X.Zhu

  • J.Knox

  • A-L.Cheng

  • A.B.Siegel

  • O.Bautista

  • M.Kudo

Medical Centers

  • Med-Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA

  • Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China

  • Dept of Neurology, Massachusetts General Hosp, Boston, MA

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Oncology, Merck & Co., Inc., Kenilworth, NJ, USA

  • Kinki University Faculty of Medicine, Osaka, Japan

Locations

  • United States

  • China

  • Canada

  • Taiwan

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Solute Carrier Family 12 Member 2

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

  • Ajicef

  • Sorafenib

  • Fuldazin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved